Extracellular Vesicles from Plasma of Patients with Glioblastoma Promote Invasion of Glioblastoma Cells Even After Tumor Resection DOI Creative Commons
Ekaterina N. Lyukmanova, Artem V. Kirichenko, Igor Medyanik

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2834 - 2834

Published: Dec. 13, 2024

Background: Glioblastoma (GB) is a highly aggressive tumor, whose progression mediated by secretion of extracellular vesicles (EVs), which can pass the brain–blood barrier and be found in plasma. Here, we performed comparative analysis effects EVs from plasma healthy donors (hEVs) GB patients before (bEVs) after (aEVs) tumor surgical resection on invasion normal astrocytes cells. Methods: We transwell assay, analyzed MAP kinases activation Western blotting, studied SNAI1/SNAI2 cellular localization confocal microscopy, measured cadherins expression flow cytometry, cytokines, regulate migration inflammation, immunoassay. Results: hEVs did not affect cells, there was down-regulated astrocytes, while increased E- N-cadherin inflammation adhesion regulators both bEVs enhanced cells but via AKT, JNK1/2/3, p38 activation, stimulated clasterization SNAI1 cell nucleus, promoted an E/N cadherin switch, caused aEVs exhibited most pro-oncogenic (stimulation invasion, nuclear localization, JNK1/2/3 cells). However, were less pronounced than those bEVs. Conclusions: In our study, revealed common different plasma-derived hEVs, aEVs, stimulate some Being tumorigenic then bEVs, are still able to promote probably remaining resection.

Language: Английский

Hsp70 and Calcitonin Receptor Protein in Extracellular Vesicles from Glioblastoma Multiforme: Biomarkers with Putative Roles in Carcinogenesis and Potential for Differentiating Tumor Types DOI Open Access
Giusi Alberti, Christian M. Sánchez‐López, Antonio Marcilla

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(6), P. 3415 - 3415

Published: March 18, 2024

Glioblastoma multiforme (GBM) is a malignancy of bad prognosis, and advances in early detection treatment are needed. GBM heterogenous, with varieties differing within tumor patient between patients. Means needed to distinguish these GMB forms, so that specific strategies can be deployed for management. We study the participation chaperone system (CS) carcinogenesis. The CS dynamic, its members moving around body extracellular vesicles (EVs) interacting components other physiological systems health disease, including GBM. Here, we describe finding high amounts Hsp70 (HSPA1A) calcitonin receptor protein (CTR) EVs patients present standardized protocol collecting, purifying, characterizing carrying CTR plasma-derived from were obtained just before ablative surgery (T0) 7 days afterwards (T1); was highly elevated at T0 less T1, greatly increased reduced below normal values T1. Our results encourage further research assess as biomarkers differentiating forms determine their roles

Language: Английский

Citations

6
Exosomes as drug delivery systems in glioma immunotherapy DOI Creative Commons
Xinqing Hao, Shiming Wang, Liang Wang

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: June 18, 2024

Abstract Recently, the significant benefits of cancer immunotherapy for most cancers have been demonstrated in clinical and preclinical studies. However, efficacy these immunotherapies gliomas is limited, owing to restricted drug delivery insufficient immune activation. As carriers, exosomes offer advantages low toxicity, good biocompatibility, intrinsic cell targeting, which could enhance glioma efficacy. a review exosome-based systems has not presented. This introduces current problems role addressing issues. Meanwhile, preparation application strategies are discussed, especially enhancing immunogenicity reversing immunosuppressive tumor microenvironment. Finally, we briefly describe challenges translation. We anticipate that this will guide use as carriers immunotherapy. Graphical

Language: Английский

Citations

6
Extracellular vesicles as drug and gene delivery vehicles in central nervous system diseases DOI Creative Commons

Xi Shi,

Weilong He,

Ashwin Gupta

et al.

Biomaterials Science, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

This review summarizes naïve extracellular vesicles (EVs) in clinical trials for central nervous system (CNS) diseases and updates recent translational preclinical research on EV-loaded drugs or genes CNS treatments.

Language: Английский

Citations

0
Addressing the Blood-Brain Barrier: Overcoming Glioblastoma Drug Delivery DOI
Ly Porosk, Ülo Langel

Methods in pharmacology and toxicology, Journal Year: 2025, Volume and Issue: unknown, P. 83 - 104

Published: Jan. 1, 2025

Language: Английский

Citations

0
Exosomes in glioma: mechanistic insights on biological, therapeutic, and diagnostic perspective DOI
Reetika Tandon, Samarth Kumar, Mayank Handa

et al.

Therapeutic Delivery, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 12

Published: Feb. 16, 2025

Gliomas are prominent and frequent primary malignant brain tumors, with a generally poor prognosis. Current treatment involves radiation, surgery chemotherapy. Exosomes nanoscale extracellular vesicles released by cells that enable biological molecule movement encourage intercellular communication in the tumor microenvironment. This contributes to glioma development, radiation resistance, overcomes Exosome functional structural properties essential for understanding cancer molecular mechanisms. They can also treat invasive tumors like glioblastomas serve as diagnostic markers. Recent research depicted exosomes' role cell maintenance, signaling, microenvironment modification. hold nucleic acids, proteins, lipids, mRNAs, lncRNAs, miRNAs, immunological regulatory molecules depending on origin of cell. paper reviews exosomes, their etiology, perspective therapeutic uses.

Language: Английский

Citations

0
Role of Extracellular Vesicles in the Progression of Brain Tumors DOI Creative Commons
Gabriella Schiera, Carlo Maria Di Liegro,

Francesco Vento

et al.

Biology, Journal Year: 2024, Volume and Issue: 13(8), P. 586 - 586

Published: Aug. 2, 2024

Brain tumors, and, in particular, glioblastoma (GBM), are among the most aggressive forms of cancer. In spite advancement available therapies, both diagnosis and treatments still unable to ensure pathology-free survival GBM patients for more than 12–15 months. At basis poor ability cope with brain we can consider: (i) intra-tumor heterogeneity; (ii) heterogeneity tumor properties when compare different patients; (iii) blood–brain barrier (BBB), which makes difficult isolation tumor-specific biomarkers delivering therapeutic drugs brain. Recently, it is becoming increasingly clear that cancer cells release large amounts extracellular vesicles (EVs) transport metabolites, proteins, classes RNAs, DNA, lipids. These structures involved pathological process characterize any particular form Moreover, EVs able cross BBB directions. Starting from these observations, researchers now evaluating possibility use purified organic fluids (first all, blood saliva), order obtain, through non-invasive methods (liquid biopsy), biomarkers, perhaps, also obtaining nanocarriers targeted drugs.

Language: Английский

Citations

3
Extracellular vesicles as delivery vehicles and therapeutic agents for glioblastoma treatment: A systematic review of in vitro and in vivo preclinical studies DOI Creative Commons
J. C. Ng, Nabil Ajwad, Shing Cheng Tan

et al.

Asian Journal of Pharmaceutical Sciences, Journal Year: 2025, Volume and Issue: unknown, P. 101043 - 101043

Published: March 1, 2025

Language: Английский

Citations

0
Pediatric gliomas immunity challenges and immunotherapy advances DOI
Eleni‐Kyriaki Vetsika, Maria A. Katsianou, Panagiotis Sarantis

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217640 - 217640

Published: March 1, 2025

Language: Английский

Citations

0
Role of Exosome in Solid Cancer Progression and Its Potential Therapeutics in Cancer Treatment DOI Creative Commons

Nada Aakel,

R.A.A. Mohammed,

Afshan Fathima

et al.

Cancer Medicine, Journal Year: 2025, Volume and Issue: 14(9)

Published: May 1, 2025

ABSTRACT Background Exosomes are extracellular vesicles ranging from 40 to 100 nm in diameter that mediate intercellular communication by transferring proteins, lipids, nucleic acids, and other metabolites. In the context of cancer, exosomes influence tumor microenvironment carrying regulatory RNAs such as miRNA, circRNA, lncRNA. They originate various cells, including adipocytes, fibroblasts, hepatocellular carcinoma (HCC) can either promote or inhibit cancer progression through pathways like MAPK PI3K‐Akt. Aim This review aims explore role solid cancers, emphasizing their self‐induced activation mechanisms how they modulate behavior. Methodology A comprehensive recent literature was conducted, focusing on studies investigated biological functions progression, molecular cargo, cellular origin, involvement signaling pathways. Results Findings multiple indicate cancer‐derived contribute proliferation, metastasis, therapy resistance enhancing within microenvironment. These activate oncogenic serve biomarkers therapeutic targets due disease modulation. Conclusion play a pivotal offer significant potential advancing our understanding biology. Their capacity key facilitate makes them promising candidates for novel diagnostic strategies.

Language: Английский

Citations

0
Exploring emerging concepts of exosomes for the diagnosis, prognosis, and therapeutics of brain cancers DOI Creative Commons
Subhrajyoti Banerjee, Vriti Sharma, Chitrangada Das Mukhopadhyay

et al.

Extracellular Vesicle, Journal Year: 2024, Volume and Issue: 3, P. 100038 - 100038

Published: April 21, 2024

Brain cancers, a global menace with high mortality rates, remain profound challenge, particularly in treating the most lethal type of malignant tumors like glioblastoma multiforme (GBM). The crucial need for prompt identification and precise prognosis drives exploration exosomes as non-invasive tools. Exosomes are generated by various cells, especially facilitating intercellular communication tumor microenvironment, fostering glioma progression conveying molecular modifiers, offering insights. These attributes hold promise enhancing diagnosis prognosis. nanosized messengers influence cancer dynamics, aiding tailored treatment strategies improved patient outcomes. This article outlines significance progression, highlighting recent advancements diagnostic therapeutic utilizing bioactive molecules biomarkers miRNAs, circ-RNAs, genes, proteins variety brain tumors, supported advanced isolation techniques. relevance circulating to malignancies glioblastoma, astrocytoma, craniopharyngiomas, meningioma, more, has been discussed. It elucidates immune cross-talk underscores diagnostic-worthy exosomal proteins. Additionally, it delineates promising avenues forthcoming investigations.

Language: Английский

Citations

3